Targeted proapoptotic LHRH-BH3 peptide

Related Experiment Video

Updated: Sep 25, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Sonia S Dharap1, Tamara Minko

  • 1Department of Pharmaceutics, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey, USA.

Pharmaceutical Research
|June 24, 2003
PubMed
Abstract

Insights

A novel targeted proapoptotic peptide, LHRH-BH3, effectively induces cancer cell death by targeting LHRH receptors and inhibiting antiapoptotic proteins. This peptide shows promise for developing new cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cancer cells often overexpress LHRH receptors.
  • Targeting cancer-specific receptors can enhance drug delivery.
  • Apoptosis pathways are crucial in cancer development and treatment.

Purpose of the Study:

  • To construct and evaluate a novel targeted proapoptotic peptide for cancer treatment.
  • To assess the anticancer activity of a peptide combining LHRH targeting and BH3 apoptosis induction.
  • To investigate the molecular mechanisms of the peptide's anticancer effects.

Main Methods:

  • Conjugation of luteinizing hormone-releasing hormone (LHRH) peptide with a synthetic BCL-2 homology 3 (BH3) domain peptide.
  • Evaluation of the synthesized LHRH-BH3 peptide's anticancer activity on various cancer cell lines.
  • Analysis of apoptosis induction, caspase activation, and BCL-2 protein family inhibition.

Main Results:

  • LHRH receptors are overexpressed on cancer cells but not healthy organs.
  • LHRH-BH3 peptide demonstrated significant cytotoxicity in cancer cell lines, unlike individual components.
  • The peptide induced apoptosis via simultaneous inhibition of BCL-2 family proteins and activation of caspase pathways.

Conclusions:

  • The LHRH-BH3 peptide represents a novel anticancer agent targeting both extracellular cancer-specific receptors and intracellular apoptosis mechanisms.
  • This dual-targeting strategy offers a promising new approach for the treatment of various cancers.
  • Further development of this peptide could lead to innovative cancer therapies.

More Related Videos

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized by phagocytes.